Stem Cell Transplant Complications
100
18
24
33
Key Insights
Highlights
Success Rate
87% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
5.0%
5 terminated out of 100 trials
86.8%
+0.3% vs benchmark
11%
11 trials in Phase 3/4
24%
8 of 33 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 33 completed trials
Clinical Trials (100)
Menin-Inhibitor Targeted Maintenance in AML
Nonmyeloablative Stem Cell Transplant in Children With Sickle Cell Disease and a Major ABO-Incompatible Matched Sibling Donor
A Study to Evaluate Tabelecleucel in Participants With Epstein Barr Virus (EBV) Associated Diseases
Horizons Chronic Graft-Versus-Host-Disease Study
A Novel Digital Application (SHIFT) to Improve Outcomes for Hematopoietic Stem Cell Transplant Survivors
Intestinal Microbiota in Stem Cell Transplant Transplant Admission
A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy
Loratadine for the Prevention of G-CSF-related Bone Pain
Prehabilitation Exercise Training in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation
Addition of Venetoclax to Combined Hematopoietic Stem Cell and Kidney Transplantation
Multidisciplinary Intervention In Chronic GVHD
Novel First-line Therapies for Grade II Acute GVHD(Graft-versus-host Disease )
The Patients' Experience After Stem Cell Transplant
Using Ultrasound Elastography to Predict Development of Hepatic Sinusoidal Obstruction Syndrome
Muscle Dysfunction in Patients With Hematological Diseases Referred to Stem Cell Transplant
The Use of Eltrombopag Post HSCT in BMFD
Delirium in Children Undergoing Stem Cell Transplantation
IS-free Treg HaploHCT
Ciprofloxacin Versus Levofloxacin in Stem Cell Transplant
Efficacy of Fluticasone Propionate Associated With Salmeterol Using Inhalation Chamber Versus Placebo to Improve the Respiratory Function in Children Over Six Years of Age Who Underwent Allogeneic Hematopoietic Stem Cell Transplantation With a Decline of FEV1 ≥10% From Pre Transplantation